William Blair Reaffirms “Outperform” Rating for Neurogene (NASDAQ:NGNE)

William Blair reaffirmed their outperform rating on shares of Neurogene (NASDAQ:NGNE) in a report released on Tuesday morning,RTT News reports. William Blair also issued estimates for Neurogene’s Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS, Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS, Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.60) EPS.

Separately, HC Wainwright decreased their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $59.80.

Neurogene Trading Down 5.0 %

Shares of NASDAQ NGNE opened at $15.33 on Tuesday. Neurogene has a 12 month low of $13.47 and a 12 month high of $74.49. The firm has a market capitalization of $227.73 million, a PE ratio of -3.59 and a beta of 1.01. The firm has a fifty day simple moving average of $16.92 and a two-hundred day simple moving average of $28.96.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05. The firm had revenue of $0.93 million during the quarter. On average, sell-side analysts predict that Neurogene will post -4.27 earnings per share for the current year.

Insider Transactions at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares of the company’s stock, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 9.92% of the company’s stock.

Institutional Investors Weigh In On Neurogene

Institutional investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its holdings in Neurogene by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock valued at $1,272,000 after purchasing an additional 741 shares during the last quarter. Virtus ETF Advisers LLC increased its stake in Neurogene by 45.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company’s stock worth $73,000 after buying an additional 989 shares during the period. Rhumbline Advisers lifted its holdings in Neurogene by 9.2% during the 4th quarter. Rhumbline Advisers now owns 15,704 shares of the company’s stock valued at $359,000 after buying an additional 1,326 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Neurogene by 34.5% during the fourth quarter. Wells Fargo & Company MN now owns 5,444 shares of the company’s stock worth $124,000 after acquiring an additional 1,397 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Neurogene by 192.8% during the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock valued at $91,000 after acquiring an additional 1,429 shares in the last quarter. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.